The Liver Meeting 2019-Co-Localization in HCV Care

Video Transcription

Video Summary

Dr. Taylor discussed the importance of prioritizing treatment for people who inject drugs, who carry a high burden of hepatitis C. He highlighted the effectiveness of direct-acting antivirals (DAAs) for this population and emphasized the need for integrated care that combines hep C and addiction expertise. He shared insights from successful models in Rhode Island and Switzerland, showcasing co-located care in methadone clinics and primary care settings. Dr. Taylor addressed challenges such as stigma, funding, and sustainability of programs. The session emphasized the importance of engaging people who inject drugs in hep C elimination efforts, promoting harm reduction, and expanding access to evidence-based opioid agonist therapy and hep C care. The discussion also touched on the role of telemedicine in bridging gaps in care delivery for this population.

Asset Caption

Presenter: Lynn E. Taylor

Keywords

treatment prioritization

people who inject drugs

hepatitis C burden

direct-acting antivirals

integrated care

stigma challenges

telemedicine role